Skyrizi patent?

What is the Skyrizi patent situation?

Skyrizi is a medication used to treat moderate to severe plaque psoriasis and active ankylosing spondylitis. The Skyrizi patent details are owned by AbbVie Pharmaceuticals, a multinational pharmacy company.

What does the Skyrizi patent cover?

The Skyrizi patent, officially known as risankizumab-rzaa, is a humanized monoclonal antibody that targets the interleukin-23 receptor (IL-23). This specific patent [1] details the composition, preparation, and use of this medication in treating various inflammatory conditions.

Why is the Skyrizi patent important?

The Skyrizi patent has significant commercial value for AbbVie, as it protects their proprietary medication from generic competition. According to DrugPatentWatch.com, the Skyrizi patent (US10745493) is set to expire on August 3, 2029 [2]. However, it's essential to note that patent protection can be extended through various mechanisms, such as patent term restoration or new patent filings.

What's the current market status for generic Skyrizi?

At present, there are no generic or biosimilar versions of Skyrizi approved for the US market. Biosimilar applicants are expected to wait for the patent to expire before seeking regulatory approval. Pharmaceutical companies may start developing biosimilars in anticipation of the patent expiration, but these applications will be subject to rigorous review processes by the FDA.

What's the future outlook for the Skyrizi patent?

AbbVie's continued success with Skyrizi may lead to new patent filings, protecting their intellectual property in the face of increasing competition. As the market for psoriasis and ankylosing spondylitis treatments grows, we can expect the Skyrizi patent situation to evolve along with it.

References:
[1] https://www.patentscope.org/search/enUS?q=US10745493
[2] https://www.drugpatentwatch.com/patent/US10745493

Sources:

1. DrugPatentWatch.com
2. PatentScope.org